Hair for the Long Haul: Alopecia Areata Cases and Considerations

At the 2025 Fall Clinical Dermatology Conference, experts discussed the long-term management of alopecia areata (AA) using JAK inhibitors, which have significantly changed the treatment landscape. Three JAK inhibitors—baricitinib, ritlecitinib, and deuroxolitinib—are now approved for use. The session focused on real-world case examples to address key management considerations such as treatment eligibility, dose adjustment, response monitoring, and patient counseling. The goal was to fill knowledge gaps and improve clinical decision-making to ensure the safe and effective use of JAK inhibitors in treating AA.